Refractory Thyroid Cancer, Thyroid, Thyroid Cancer
Conditions
Keywords
RAI refractory thyroid cancer, thyroid cancer, thyroid, Refractory Thyroid Cancer, Radio-iodine refractory thyroid cancer, 22-320, Memorial Sloan Kettering Cancer Center
Brief summary
The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.
Interventions
OTHERSurveillance Visit
Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients ≥ 18 years old at time of consent Inclusion Criteria: * Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI. * Patients who will receive redifferentiation agents prior to planned diagnostic and/or therapeutic use of radioactive iodine as part of routine clinical care. * Patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as part of routine clinical care prior to diagnostic and/or therapeutic radioactive iodine administration. * Patients previously treated with redifferentiation agents as part of clinical care prior to diagnostic and/or therapeutic radioactive iodine administration who are willing to provide retrospectively collected data surrounding the time of the previous treatment and will provide prospective data from the time of consent.
Exclusion criteria
* RAI refractory thyroid cancer patients that will receive redifferentiation agents prior to diagnostic and/or therapeutic use of radioactive iodine as part of a prospective clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events will be collected in every visit | 2 years | The primary objective of this protocol is to prospectively collect data on patients with radio-iodine refractory thyroid cancer or patients unlikely to respond to radioactive iodine prior, during and after initiation of redifferentiating agents used as part of routine clinical care with or without radioactive iodine treatment. |
Countries
United States
Contacts
CONTACTLaura Boucai, MD
CONTACTAlan Ho, MD, PhD
PRINCIPAL_INVESTIGATORLaura Boucai, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed